• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Eli Lilly and Company

    10/23/24 5:17:34 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LLY alert in real time by email
    SC 13G/A 1 lilly241106_sc13ga.htm SC 13G/A

     

         
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     
         
     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 40)

     

     

     
      Eli Lilly and Company  
     

     

    (Name of Issuer)

    Common Stock, Without Par Value

     
     

     

    (Title of Class of Securities)

    532457-10-8

     
     

     

    (CUSIP Number)

    September 30, 2024

     
     

     

    (Date of Event Which Requires Filing of this Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)

     

    o Rule 13d-1(c)

     

    ü Rule 13d-1(d)

     

    The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

    1 of 5

     

     

    CUSIP No. 532457-10-8 13G  

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).

     

    LILLY ENDOWMENT INC.

    35-0868122

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) ¨

    (b) ¨

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    INDIANA

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

     

    5

    SOLE VOTING POWER

    96,891,978

     

    6

    SHARED VOTING POWER

    0

     

    7

    SOLE DISPOSITIVE POWER

    96,891,978

     

    8

    SHARED DISPOSITIVE POWER

    0

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    96,891,978

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (See Instructions)

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    10.20%

    12

    TYPE OF REPORTING PERSON

    CO

           

     Footnote:

    The percent of class represented is based on 950,425,778 shares of common stock outstanding as of August 5, 2024, as reported on the Issuer's Form 10-Q for the period ended June 30, 2024.

    2 of 5

     

    Item 1.

    (a)Name of Issuer

    Eli Lilly and Company

     

    (b)Address of Issuer's Principal Executive Offices

    Lilly Corporate Ctr, Drop Code 1094

    Indianapolis, Indiana, 46285

     

     

    Item 2.

    (a)Name of Person Filing

    This statement is filed by Lilly Endowment Inc., a not for profit corporation organized under the laws of the State of Indiana. Lilly Endowment Inc. is an organization described in Section 501(c)(3) of the Internal Revenue Code of 1986 and is a private foundation under Section 509(a) of the Code.

     

    (b)Address of Principal Business Office or, if none, Residence

    The address of the principal business office of Lilly Endowment Inc. is 2801 North Meridian Street, Indianapolis, Indiana 46208.

     

     

    (c)Citizenship

    Indiana

     

    (d)Title of Class of Securities

    Common Stock, Without Par Value

     

    (e)CUSIP Number

    532457-10-8

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
         
     (b)o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c):
         
     (c)o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
         
     (d)o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
         
     (e)o An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
         
     (f)o An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
         
     (g)o A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
         
     (h)o A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
     (i)o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the
    Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
     (j)o Group, in accordance with§ 240.13d-l(b)(I)(ii)(J).

    3 of 5

     

     

    Item 4.Ownership

     

    (a)Amount Beneficially Owned
       
      96,891,978

     

    (b)Percent of Class
       
      10.20%

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote
         
        96,891,978
         
       (ii) Shared power to vote or to direct the vote
         
        0
         
       (iii)Sole power to dispose or to direct the disposition of
         
        96,891,978
         
       (iv) Shared power to dispose or to direct the disposition of
         
        0

     

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.

     

    Not Applicable.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

    Not Applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not Applicable

     

    Item 8.Identification and Classification of Members of the Group

    Not Applicable

     

    Item 9.Notice of Dissolution of Group

    Not Applicable

     

    Item 10.Certification

     

    Not Applicable

    4 of 5

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: October 21, 2024 Lilly Endowment Inc.
       
      By: /s/ Diane M. Stenson
      Name: Diane M. Stenson
      Title: Vice President & Treasurer

     

    Footnotes: Item 4: This information is provided as of September 30, 2024.
       
      Item 4(a): None of such shares are deemed to be beneficially owned by reason of the possession of Lilly Endowment Inc. of a right to acquire such shares.
       
      Item 4(b): The percent of class represented is based on shares of common stock outstanding as of August 5, 2024, as reported on the Issuer's Form 10-Q for the period ended June 30, 2024.

     

    5 of 5 

    Get the next $LLY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LLY

    DatePrice TargetRatingAnalyst
    8/18/2025$700.00Outperform → Neutral
    Daiwa Securities
    8/7/2025$715.00Outperform → Market Perform
    Leerink Partners
    6/5/2025Buy → Hold
    Erste Group
    4/28/2025$1150.00 → $700.00Buy → Reduce
    HSBC Securities
    4/22/2025$975.00Overweight
    Cantor Fitzgerald
    12/10/2024$997.00Buy
    BofA Securities
    11/15/2024$1000.00Outperform
    Wolfe Research
    10/17/2024$1100.00Outperform
    Bernstein
    More analyst ratings

    $LLY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Eli Lilly downgraded by Daiwa Securities with a new price target

    Daiwa Securities downgraded Eli Lilly from Outperform to Neutral and set a new price target of $700.00

    8/18/25 8:49:16 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eli Lilly downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Eli Lilly from Outperform to Market Perform and set a new price target of $715.00

    8/7/25 9:51:18 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eli Lilly downgraded by Erste Group

    Erste Group downgraded Eli Lilly from Buy to Hold

    6/5/25 7:52:21 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & CFO Montarce Lucas bought $494,627 worth of shares (715 units at $691.79), increasing direct ownership by 5% to 14,685 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/15/25 4:13:02 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Alvarez Ralph bought $500,473 worth of shares (758 units at $660.25) (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/14/25 4:12:51 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & Pres., Lilly Oncology Van Naarden Jacob bought $647,360 worth of shares (1,000 units at $647.36), increasing direct ownership by 5% to 20,562 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/13/25 4:15:45 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $LLY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $LLY
    SEC Filings

    View All

    $LLY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    EVP & CFO Montarce Lucas bought $494,627 worth of shares (715 units at $691.79), increasing direct ownership by 5% to 14,685 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/15/25 4:13:02 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Alvarez Ralph bought $500,473 worth of shares (758 units at $660.25) (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/14/25 4:12:51 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & Pres., Lilly Oncology Van Naarden Jacob bought $647,360 worth of shares (1,000 units at $647.36), increasing direct ownership by 5% to 20,562 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/13/25 4:15:45 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 31, 2024 - FDA Roundup: May 31, 2024

    For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa

    5/31/24 3:22:42 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 7, 2024 - FDA Roundup: May 7, 2024

    For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ

    5/7/24 4:10:24 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    December 5, 2023 - FDA Roundup: December 5, 2023

    For Immediate Release: December 05, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, registration opened for the FDA’s virtual Rare Disease Day on Friday, March 1, 2024. This year’s Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss efforts to address the unique challenges with developing treat

    12/5/23 5:00:21 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form FWP filed by Eli Lilly and Company

    FWP - ELI LILLY & Co (0000059478) (Subject)

    8/18/25 5:28:50 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Eli Lilly and Company

    10-Q - ELI LILLY & Co (0000059478) (Filer)

    8/7/25 9:59:55 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eli Lilly and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ELI LILLY & Co (0000059478) (Filer)

    8/7/25 7:05:40 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly reports second-quarter 2025 financial results and raises guidance

    Revenue in Q2 2025 increased 38% to $15.56 billion driven by volume growth from Zepbound and Mounjaro. Increased the midpoint of our 2025 full-year revenue guidance by $1.5 billion to be in the range of $60 billion to $62 billion; reported EPS guidance raised to be in the range of $20.85 to $22.10 and non-GAAP EPS guidance raised to be in the range $21.75 to $23.00.Pipeline progress included positive results in orforglipron for obesity, Mounjaro SURPASS CVOT for type 2 diabetes and heart disease, and Jaypirca H2H vs Imbruvica in CLL/SLL.Q2 2025 EPS increased 92% to $6.29 on a reported basis and increased 61% to $6.31 on a non-GAAP basis, both inclusive of $0.14 of acquired IPR&D charges.Busi

    8/7/25 6:45:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity

    In ATTAIN-1, the investigational once-daily oral pill showed significant efficacy, and a safety and tolerability profile consistent with injectable GLP-1 therapies at 72 weeks Orforglipron achieved the primary and all key secondary endpoints, including demonstrating improvements in a number of cardiovascular risk factors With these results, Lilly is on track to submit orforglipron to global regulatory agencies by year-end and is making substantial investments to meet anticipated demand at launch INDIANAPOLIS, Aug. 7, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced positive topline results from the Phase 3 ATTAIN-1 trial, evaluating orforglipron, an investigational oral

    8/7/25 6:25:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease

    Mounjaro met the primary objective of non-inferiority vs. Trulicity with an 8% lower rate of MACE-3 events, while delivering greater reductions in A1C and weight In the trial, Mounjaro was associated with a 16% lower rate of all-cause death compared to Trulicity, suggesting more comprehensive health benefits Results from the largest and longest Mounjaro trial to date reaffirm its established safety and tolerability profile INDIANAPOLIS, July 31, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced topline results from SURPASS-CVOT, a first-of-its-kind head-to-head Phase 3 cardiovascular outcomes trial comparing two incretin therapies in adults with type 2 diabetes and estab

    7/31/25 6:45:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    Financials

    Live finance-specific insights

    View All

    Lilly reports second-quarter 2025 financial results and raises guidance

    Revenue in Q2 2025 increased 38% to $15.56 billion driven by volume growth from Zepbound and Mounjaro. Increased the midpoint of our 2025 full-year revenue guidance by $1.5 billion to be in the range of $60 billion to $62 billion; reported EPS guidance raised to be in the range of $20.85 to $22.10 and non-GAAP EPS guidance raised to be in the range $21.75 to $23.00.Pipeline progress included positive results in orforglipron for obesity, Mounjaro SURPASS CVOT for type 2 diabetes and heart disease, and Jaypirca H2H vs Imbruvica in CLL/SLL.Q2 2025 EPS increased 92% to $6.29 on a reported basis and increased 61% to $6.31 on a non-GAAP basis, both inclusive of $0.14 of acquired IPR&D charges.Busi

    8/7/25 6:45:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly confirms date and conference call for second-quarter 2025 financial results announcement

    INDIANAPOLIS, July 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will announce its second-quarter 2025 financial results on August 7, 2025. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.  The conference call will begin at 8:30 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call.  About LillyLilly is a medicine company turning science into hea

    7/24/25 10:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly declares third-quarter 2025 dividend

    INDIANAPOLIS, June 23, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the third quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on September 10, 2025, to shareholders of record at the close of business on August 15, 2025. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new dis

    6/23/25 11:37:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    Leadership Updates

    Live Leadership Updates

    View All

    New AI Rollouts Signal Shift From Hype to Healthcare Reality

    USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- With populations again, and chronic diseases on the rise, global healthcare systems are facing enormous challenges ahead. However, there is hope on the horizon to alleviate some of these burdens, coming from the rise of AI in healthcare, as the new tech is proving it can improve diagnostic accuracies, drug discoveries, and administration work flow. Healthcare leaders are already reporting benefits, including reduced clinician workloads through voice-based AI tools and the use of AI agents to boost efficiency and support smarter care delivery. Behind the scenes, the tech is b

    6/24/25 9:45:00 AM ET
    $LLY
    $PHG
    $PLTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Electronics
    Computer Software: Prepackaged Software

    Asha Therapeutics Awarded Barnett Drug Development Grant by the ALS Association to Advance Novel Intra-Molecular Glue Inhibitor of SARM1 to Clinic and Announces Appointment of Disarm Therapeutics' Founders to Company's Scientific Advisory Board

    Asha Therapeutics (Asha), a life sciences company pioneering breakthrough therapeutics for neurological disease, announced today the company has been awarded a grant from the ALS Association through its Lawrence and Isabel Barnett Drug Development Program for the advancement of ASHA-624, a novel brain-penetrant intra-molecular glue inhibitor of SARM1. The grant will support the continued development of ASHA-624 towards first-in-human clinical trials as a potential disease-modifying therapeutic for Amyotrophic Lateral Sclerosis (ALS). ASHA-624 was designed using Asha's proprietary PRISM™ drug design technology, which creates new medicines to restore normal biology and provide functional cu

    11/13/24 9:30:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly appoints Lucas Montarce as executive vice president and chief financial officer

    INDIANAPOLIS, Sept. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of Lucas Montarce as executive vice president and chief financial officer (CFO) and member of the company's Executive Committee, effective immediately. Since joining Lilly in 2001, Montarce has held a range of finance leadership roles, including serving as group vice president, corporate controller and chief financial officer of Lilly Research Laboratories; vice president, finance and chief financial officer of Lilly International; and vice president, finance and global chief financial officer of Elanco Health. He most recently served in the role of Lilly president and general manage

    9/9/24 6:45:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Eli Lilly and Company

    SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

    10/23/24 5:17:34 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Eli Lilly and Company (Amendment)

    SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

    2/13/24 5:04:42 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Eli Lilly and Company (Amendment)

    SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

    1/26/24 4:25:45 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care